Skip to main content

Advertisement

SpringerLink
Log in

Intravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months (Report 1)

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

The goal of this work is to compare the visual and anatomical (central macular thickness; CMT) outcomes of intravitreal bevacizumab (IVB) injections relative to sham treatment in eyes with acute (less than 3 months in duration) branch retinal vein occlusion (BRVO).

Methods

In a double-masked randomized clinical trial (RCT), patients with acute BRVO were randomly assigned to one of two treatment groups: IVB (two injections of 1.25 mg IVB 6 weeks apart) or sham treatment. Primary outcome measures included changes in best-corrected visual acuity (BCVA) and CMT in optical coherence tomography (OCT) during follow-up (FU) examinations. Any complications secondary to injections were considered secondary outcomes. FU results after 6 and 12 weeks are reported.

Results

Eighty-one eyes (43 OD) of 81 patients (47 females) were enrolled in the study. Forty-two patients were enrolled in the IVB group, and 39 patients were enrolled in the sham group. Visual acuity and CMT improved in the IVB group after week 6 (two Snellen lines and 262 μm, respectively) and week 12 (three Snellen lines and 287 μm, respectively). After week 6, visual improvements in the IVB group were significantly increased relative to that of the sham group. However, visual improvements at week 12 were not significantly different between the two groups (1.5 Snellen lines visual improvement in the sham group at week 12).

Conclusions

In acute BRVO, two IVB injections resulted in significant improvement of vision and CMT at 6 weeks relative to the sham group. However, the visual improvements in the IVB group were not significantly different from those in the sham group at 12 weeks. IVB injections accelerate an initial improvement of visual acuity but do not have any significant effects on vision after 12 weeks.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 3
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. The Branch Vein Occlusion Study Group (1984) Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 98:271–282

    Google Scholar 

  2. Mitchell P, Smith W, Chang A (1996) Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 114:1243–1247

    CAS  PubMed  Google Scholar 

  3. Cugati S, Wang JJ, Knudtson MD, Rochtchina E, Klein BE, Wong TY, Mitchell P (2007) Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts. Ophthalmology 114:520–524

    Article  PubMed  Google Scholar 

  4. Greer DV, Constable IJ, Cooper RL (1980) Macular oedema and retinal branch vein occlusion. Aust J Ophthalmol 8:207–209

    Article  CAS  PubMed  Google Scholar 

  5. Kalogeropoulos C, Donati G, Pizzolato GP, Pournaras CJ (1996) Morphology of early retinal lesions after experimental venous occlusion. Klin Monatsbl Augenheilkd 208:375–376

    Article  CAS  PubMed  Google Scholar 

  6. Larsson J, Bauer B, Andreasson S (2000) The 30-Hz flicker cone ERG for monitoring the early course of central retinal vein occlusion. Acta Ophthalmol Scand 78:187–190

    Article  CAS  PubMed  Google Scholar 

  7. Lang GE, Handel A (1993) Results of laser coagulation of branch retinal vein occlusions. Klin Monatsbl Augenheilkd 203:180–188

    Article  CAS  PubMed  Google Scholar 

  8. Esrick E, Subramanian ML, Heir JS, Ak D, Topping TM, Frederick AR, Morley MG (2005) Multiple laser treatments for macular edema attributable to branch retinal vein occlusion. Am J Ophthalmol 139:653–657

    Article  PubMed  Google Scholar 

  9. Cekic O, Chang S, Tseng JJ, Barile GR, Del Priore LV, Weissman H, Schiff WM, Ober MD (2005) Intravitreal triamcinolone injection for treatment for macular edema secondary to branch retinal vein occlusion. Retina 7:851–855

    Google Scholar 

  10. Krepler K, Ergun E, Sacu S, Richter-Muksch S, Wagner J, Stur M, Wedrich A (2005) Intravitreal triamcinolone acetonide in patients with macular oedema due to branch retinal vein occlusion: a pilot study. Acta Ophthalmol Scand 83:600–604

    Article  PubMed  Google Scholar 

  11. Ramezani A, Entezari M, Moradian S, Tabatabaei H, Kadkhodaei S (2006) Intravitreal triamcinolone for acute central retinal vein occlusion; a randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 244(12):1601–1606

    Article  CAS  PubMed  Google Scholar 

  12. Chen SD, Sundaram V, Lochhead J, Patel CK (2006) Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 141:876–883

    Article  CAS  PubMed  Google Scholar 

  13. Ozkiris A, Evereklioglu C, Erkilic K, Dogan H (2006) Intravitreal triamcinolone acetonide for treatment of persistent macular edema in branch retinal vein occlusion. Eye 20:13–17

    Article  CAS  PubMed  Google Scholar 

  14. Jaissle GB, Szurman P, Bartz-Schmidt KU (2004) Ocular side effects and complications of intravitreal triamcinolone acetonide injection. Ophthalmology 101(2):121–128

    Article  CAS  Google Scholar 

  15. Kaushik S, Gupta V, Gupta A, Dogra MR, Singh R (2004) Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion. Am J Ophthalmol 137:758–760

    CAS  PubMed  Google Scholar 

  16. Thompson JT (2006) Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am J Ophthalmol 141:629–637

    Article  CAS  PubMed  Google Scholar 

  17. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonzalez VH, Singerman LJ, Tolentino M, SCORE Study Research Group (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 127(9):1115–1128

    Article  PubMed  Google Scholar 

  18. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E (1998) Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 105:412–416

    Article  PubMed  Google Scholar 

  19. Boyd SR, Zachary I, Chakravarthy U, Gj A, Wisdom GB, Cree IA, Martin JF, Hykin PG (2002) Correlation of increased vascular endothelial growth factor with neovascularization and permeability. Arch Ophthalmol 120:1644–1645

    CAS  PubMed  Google Scholar 

  20. Funk M, Kriechbaum K, Prager F, Benesch T, Georgopoulos M, Zlabinger GJ, Schmidt-Erfurth U (2009) Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 50(3):1025–1032

    Article  PubMed  Google Scholar 

  21. Aiello LP, Avery RL, Arrigg PG, Jampel HD, Shah ST, Pasquale LR (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487

    Article  CAS  PubMed  Google Scholar 

  22. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL (2007) Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 27:419–425

    Article  PubMed  Google Scholar 

  23. Rosenfeld PJ, Fung AE, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36:336–339

    PubMed  Google Scholar 

  24. Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenaver W (2007) Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 92(4):518–522

    Article  Google Scholar 

  25. Jaissle GB, Ziemssen F, Petermeier K, Szurman P, Ladewig M, Gelisken F, Völker M, Holz FG, Bartz-Schmidt KU (2006) Bevacizumab for treatment of macular edema secondary to retinal vein occlusion. Ophthalmologe 103(6):471–475

    Article  CAS  PubMed  Google Scholar 

  26. Avastin (Product monograph 2005) Gardiner- Caldwell Communications Mississauga، Ontario: Hoffmann-La Roche Ltd.

  27. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391–400

    Article  CAS  PubMed  Google Scholar 

  28. Chung EJ, Hong YT, Lee SC, Kwon OW, Koh HJ (2008) Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 246(9):1241–1247

    Article  CAS  PubMed  Google Scholar 

  29. Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK, Babu RB, Narayana KM (2007) Clinical anatomic and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 143:601–606

    Article  CAS  PubMed  Google Scholar 

  30. Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA, Jumper JM, Figueroa M (2009) SCORE Study Investigator Group SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion. Ophthalmology Mar 116(3):504–512

    Article  Google Scholar 

  31. Rench F, Jonas JB, Spandau UHM (2009) Early intravitreal bevacizumab for non-ischemic branch retinal vein occlusion. Ophthalmologica 223:124–127

    Article  Google Scholar 

  32. Jaissle GB, Leitritz M, Gelisken F, Bartz ZF, KU SSP (2009) One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 247:27–33

    Article  CAS  PubMed  Google Scholar 

  33. Matsumota Y, Freund KB, Peirettie E, Cooney MJ (2007) Rebound macular edema following bevacizumab (Avastin) therapy for venous occlusion disease. Retina 27(4):426–431

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ophthalmic Research Center, Labbafinejad Medical Center, Pasdaran Ave. Boostan 9 St., Tehran, 16666, Iran

    Siamak Moradian, Babak Sadeghi, Hamid Ahmadieh, Masoud Soheilian, Mohammad Hossein Dehghan & Mohsen Azarmina

  2. Ophthalmic Research Center, Farabi Medical Center, Qazvin Sq., Tehran, Iran

    Hooshang Faghihi, Niloofar Piri & Mohammad Riazi Esfahani

Authors
  1. Siamak Moradian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hooshang Faghihi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Babak Sadeghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Niloofar Piri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hamid Ahmadieh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masoud Soheilian
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mohammad Hossein Dehghan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mohsen Azarmina
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mohammad Riazi Esfahani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Siamak Moradian.

Additional information

Financial Disclosure(s)

The author(s) have no proprietary or commercial interest in any materials discussed in this article. The authors do not have any financial relationships with the organization that sponsored this research.

The authors have full control of all primary data and agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data upon request.

A clinical trial registration was conducted and its information is available at “www.clinicaltrials.gov” with study number of (NCT00370851).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moradian, S., Faghihi, H., Sadeghi, B. et al. Intravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months (Report 1). Graefes Arch Clin Exp Ophthalmol 249, 193–200 (2011). https://doi.org/10.1007/s00417-010-1440-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-010-1440-8

Keywords

Search

Navigation